Micro Interventional Devices initiates 1st-in-man EU study for its Permaseal
Cardiovascular medical device company Micro Interventional Devices launched a 1st-in-man European clinical study for its Permaseal cardiac closure, a device which combines soft tissue anchors and biocompatible elastomers that form a "web" around the myocardial access site, the company said.
The study will enroll 40 patients at 5 E.U. sites, and MID expects data to be available by Q1 2013.
Symetis closes 1st-in-man trial for Acurate TF aortic bioprosthesis
Swiss medical device maker Symetis completed its 1st-in-man trial of the Acurate TF aortic bioprosthesis and delivery system, a transfemoral aortic valve replacement device.
The company initiated the CE-Mark clinical study in September and hopes the system will win CE Mark approval mid-2013.
Cappella Medical: Positive long-term results for its Sideguard Technology
Medical device maker Cappella Medical unveiled long-term results for its Sideguard coronary sidebranch stent, which is designed to protect sidebranch during treatment of bifurcation disease.
On June 4-5, DeviceTalks is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring, bringing you the best and brightest minds in the industry.
Heidi Dohse: Sr. Program Manager, Healthcare, Google, Founder, Tour de Heart Foundation, Acessa Health Inc. Michael J. Pederson: Senior Vice President, Cardiac Arrhythmias and Heart Failure Division, Abbott Hon. Melvin Carter: Mayor, Saint Paul Tim Philips: Compliance Officer, FDA’s Office of Medical Device and Radiological Health Operations Dr. Myriam J. Curet, MD, FACS: Chief Medical Officer, Intuitive Surgical
Take a look at our incredible line up of speakers and join us now.
Use the code "KEYNOTE" to save 15% on the cost of registration.